Younis Husam 4

What Happened

• Younis Husam, Chief Scientific Officer of Atrium Therapeutics (RNA), received equity awards on April 20, 2026: 30,000 restricted stock units (RSUs) and an award covering 60,000 shares (reported as a derivative grant). Both awards show $0.00 purchase price in the Form 4 filing, meaning they were granted as compensation rather than bought with cash.

Key Details

• Transaction date: 2026-04-20; Form 4 filed: 2026-04-22 (timely).
• Award amounts and prices: 30,000 RSUs @ $0.00; 60,000 derivative award (option-type) @ $0.00.
• Vesting (per filing footnotes):
  • RSUs (F1): 25% vest on March 20, 2027; remaining RSUs vest in three substantially equal annual installments thereafter, subject to continued service.
  • Derivative/option (F2): 25% of shares underlying the option vest on March 20, 2027; remaining shares vest in 36 substantially equal monthly installments thereafter, subject to continued service.
• Shares owned after the transaction: not specified in the provided excerpt of the filing.
• No 10b5-1 plan, tax withholding, immediate sale, or late filing indicated in the disclosed items.

Context

• The 30,000 RSUs will convert to common shares only as they vest; the 60,000-share derivative appears to be an option-like grant that vests over time and must be exercised to become shares. These awards are typical forms of executive compensation and do not represent an open-market purchase or sale. They are informational about compensation but do not by themselves indicate the insider buying or selling shares in the market.